A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide
with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that
has returned or does not respond to treatment. Drugs used in chemotherapy, such as
irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of
tumour cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Temsirolimus may stop the growth of tumour cells by blocking some of the
enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumour
cells and help kill them or carry tumour-killing substances to them. It is not yet known
whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or
dinutuximab is more effective in treating neuroblastoma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society